ptc cell line bcpap  (Procell Inc)

Journal: Translational Cancer Research

Article Title: Identification of papillary thyroid carcinoma-associated epithelial cell subpopulations and diagnostic biomarkers: integrating machine learning with single-cell analysis

doi: 10.21037/tcr-2025-aw-2244

Figure Lengend Snippet: qRT-PCR validation of hub gene expression in PTC and normal thyroid cells. (A) Relative mRNA expression levels of XPR1 in BCPAP and NC cells, showing significant upregulation in BCPAP. (B) Relative mRNA expression levels of SH3RF1 in BCPAP and NC cells, demonstrating marked downregulation in BCPAP. (C) Relative mRNA expression levels of TLE1 in BCPAP and NC cells, indicating significant downregulation in BCPAP. ***, P<0.001. BCPAP, papillary thyroid carcinoma cell line; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; mRNA, messenger RNA; NC, normal thyroid epithelial cell; PTC, papillary thyroid carcinoma; qRT-PCR, quantitative real-time polymerase chain reaction.

Article Snippet: The PTC cell line (BCPAP) and normal thyroid epithelial cells (NC) were purchased from Procell Life Science & Technology Co., Ltd. (Wuhan, China).

Techniques: Quantitative RT-PCR, Biomarker Discovery, Gene Expression, Expressing, Real-time Polymerase Chain Reaction

Journal: European Thyroid Journal

Article Title: The mammalian acid chitinase promotes oncogenic properties of thyroid cancer cells through the JAK2/STAT3 pathway

doi: 10.1530/ETJ-24-0311

Figure Lengend Snippet: CHIA expression is elevated in thyroid cancer tissues and cells and is significantly associated with the clinicopathological features of thyroid cancer patients. (A) Representative images of immunohistochemical analysis of CHIA expression in thyroid cancer-adjacent tissues (upper panel) and thyroid cancer tissues (lower panel). The left panel (scale bars = 400 μm), the right panel (scale bars = 100 μm). (B) CHIA expression in paired thyroid cancer adjacent tissues ( n = 85) and thyroid cancer tissues ( n = 85) as determined by IHC, **** P < 0.0001, t test, compared with paired adjacent tissues. (C) CHIA expression in thyroid cancer-adjacent tissues ( n = 85) and in PTC ( n = 76), FTC ( n = 2), MTC ( n = 6) and ATC ( n = 1) tissues detected by IHC; **** P < 0.0001; one-way ANOVA; ns, not significant. Owing to the small sample sizes of the FTC ( n = 2) and ATC ( n = 1) groups, we were unable to calculate whether there were significant differences compared with the control group. (D) Representative images of immunohistochemical analysis of CHIA expression in adjacent, PTC, FTC, MTC and ATC tissues (scale bars = 100 μm). (E) Differences in CHIA expression in TNM I-II ( n = 62) and TNM III-IV ( n = 23) thyroid cancer tissues, * P < 0.05, t test. (F) Differences in CHIA expression in male ( n = 32) and female ( n = 53) thyroid cancer tissues; ns, not significant; t test. (G) This figure presents an analysis of CHIA expression in thyroid cancer ( n = 505) and adjacent normal tissues ( n = 59) based on data from the UALCAN database ( https://ualcan.path.uab.edu/cgi-bin/TCGAExResultNew2.pl?genenam=CHIA&ctype=THCA ), with samples obtained from TCGA. (H) Data from the GEO database ( GSE60542 ) were used to analyze the expression of CHIA in thyroid cancer ( n = 35) and adjacent normal tissues ( n = 30). P = 0.0018, t test. (I) CHIA protein levels were measured in the thyroid cancer cell lines BCPAP, TPC-1, KTC-1 and FTC133 and the human normal thyroid epithelial cell line Nthy-ori-3-1 by Western blot analysis ( n = 3).

Article Snippet: The normal human thyroid epithelial cell line Nthy-ori-3-1 and the thyroid cancer cell lines BCPAP (PTC), TPC-1 (PTC), KTC-1 (PTC) and FTC133 (FTC) were purchased from Procell Life Science & Technology Co., Ltd (China).

Techniques: Expressing, Immunohistochemical staining, Paraffin-embedded Immunohistochemistry, Control, Western Blot